Ai Cure Technologies speaking at 12th Conference on Antiepileptic Drug and Device Trials
NEW YORK – May 17, 2013 – Ai Cure Technologies, an artificial intelligence company providing advanced facial recognition solutions to monitor medication adherence, announced today that Adam Hanina, CEO, will be speaking about AiView®, a new computer vision solution developed to monitor medication adherence in real time, for use in antiepileptic drug research at the 12th Conference on Antiepileptic Drug and Device Trials in Avenutra, Fla.
AiView® could be potentially important for use in clinical trials involving antiepileptic drugs. Given the high risks associated with nonadherence to epilepsy treatment regimens, it is essential for study participants to maintain a strict dosing schedule. The AiView®solution is designed to reduce risk in clinical trials – both for patients and for investigators – and to improve data integrity by accurately monitoring patient adherence by confirming medication ingestion in real-time. A live audit of patient adherence rates can be accessed throughout the trial, allowing study staff to intervene in case of any patient nonadherence. The transparency of adherence rates also enables study coordinators to continuously ensure that the rate of adherence assumed in the trial’s design is continuously being met, guaranteeing high-quality data and study validity.
In addition to clinical trials, AiView® has been designed as a disease management application for use in epilepsy treatment. Despite the increased risk of morbidity and mortality, nonadherence to epilepsy treatment regimens has been extensively documented among adults and children and is often cited as a key obstacle in achieving the key therapeutic goal of no seizures. AiView®‘s interactive computer vision solution, available on smartphones and tablets, encourages optimal medication adherence through intelligent and effective reminders, positive feedback and integrated real-time care. AiView is HIPAA and 21 CFR Part 11 compliant.